Insulin lispro - Biologic Drug Details

Summary for insulin lispro

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	6
Suppliers: see list	3
Recent Clinical Trials:	See clinical trials for insulin lispro
Drug Prices:	Drug price information for insulin lispro
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for insulin lispro

Recent Clinical Trials for insulin lispro

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Diabetes & Endocrinology Foundation	N/A
Medanta, The Medicity, India	N/A
Manchester University NHS Foundation Trust	N/A

See all insulin lispro clinical trials

Recent Litigation for insulin lispro

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. v. AMNEAL PHARMACEUTICALS OF NEW YORK, LLC	2023-10-06
Novartis Pharmaceuticals Corporation v. MSN Pharmaceuticals Inc.	2022-10-24
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC	2021-11-10

See all insulin lispro litigation

PTAB Litigation

Petitioner	Date
Pfizer Inc.	2019-05-02
Mylan Pharmaceuticals Inc.	2018-10-29
Mylan Pharmaceuticals Inc	2018-09-10

See all insulin lispro litigation

Pharmacology for insulin lispro

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin lispro Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin lispro Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for insulin lispro Derived from Patent Text Search

No patents found based on company disclosures